Triodos Investment Management BV Sells 3,025 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Triodos Investment Management BV cut its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 2.2% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 133,187 shares of the medical equipment provider's stock after selling 3,025 shares during the period. Intuitive Surgical makes up 4.4% of Triodos Investment Management BV's investment portfolio, making the stock its 4th biggest holding. Triodos Investment Management BV's holdings in Intuitive Surgical were worth $44,932,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. OFI Invest Asset Management acquired a new position in Intuitive Surgical during the 3rd quarter worth approximately $25,000. Baystate Wealth Management LLC grew its holdings in Intuitive Surgical by 150.0% during the fourth quarter. Baystate Wealth Management LLC now owns 75 shares of the medical equipment provider's stock worth $25,000 after acquiring an additional 45 shares during the period. MCF Advisors LLC raised its position in Intuitive Surgical by 108.1% in the fourth quarter. MCF Advisors LLC now owns 77 shares of the medical equipment provider's stock worth $26,000 after acquiring an additional 40 shares in the last quarter. Headinvest LLC purchased a new stake in shares of Intuitive Surgical during the 3rd quarter worth $28,000. Finally, Stone House Investment Management LLC boosted its position in shares of Intuitive Surgical by 100.0% during the 3rd quarter. Stone House Investment Management LLC now owns 100 shares of the medical equipment provider's stock worth $29,000 after purchasing an additional 50 shares in the last quarter. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ISRG has been the topic of several research reports. Barclays upped their target price on Intuitive Surgical from $385.00 to $430.00 and gave the company an "overweight" rating in a report on Thursday, January 25th. Wells Fargo & Company raised their target price on shares of Intuitive Surgical from $363.00 to $416.00 and gave the company an "overweight" rating in a report on Friday, January 19th. Jefferies Financial Group upped their price target on shares of Intuitive Surgical from $365.00 to $375.00 and gave the company a "hold" rating in a report on Friday, April 19th. StockNews.com downgraded Intuitive Surgical from a "buy" rating to a "hold" rating in a research report on Thursday, February 29th. Finally, Piper Sandler increased their target price on Intuitive Surgical from $425.00 to $435.00 and gave the company an "overweight" rating in a report on Friday, April 19th. Five equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $396.17.

Intuitive Surgical Trading Up 0.9 %

ISRG stock traded up $3.31 during midday trading on Tuesday, hitting $384.19. 913,299 shares of the company's stock were exchanged, compared to its average volume of 1,573,720. The firm has a 50 day moving average price of $384.59 and a 200-day moving average price of $355.19. Intuitive Surgical, Inc. has a 12-month low of $254.85 and a 12-month high of $403.76. The stock has a market capitalization of $136.27 billion, a price-to-earnings ratio of 69.35, a price-to-earnings-growth ratio of 5.00 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last released its earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.10. The company had revenue of $1.89 billion during the quarter, compared to the consensus estimate of $1.87 billion. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The company's revenue was up 11.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.00 EPS. On average, sell-side analysts forecast that Intuitive Surgical, Inc. will post 4.8 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, VP Marshall Mohr sold 108,790 shares of the stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $385.08, for a total transaction of $41,892,853.20. Following the sale, the vice president now owns 26,877 shares in the company, valued at $10,349,795.16. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, SVP Mark Brosius sold 196 shares of the company's stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $400.00, for a total transaction of $78,400.00. Following the completion of the transaction, the senior vice president now owns 1,842 shares in the company, valued at $736,800. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Marshall Mohr sold 108,790 shares of the stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $385.08, for a total transaction of $41,892,853.20. Following the completion of the sale, the vice president now directly owns 26,877 shares in the company, valued at approximately $10,349,795.16. The disclosure for this sale can be found here. Insiders sold a total of 147,939 shares of company stock valued at $57,069,835 over the last 90 days. 0.80% of the stock is owned by company insiders.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.

Want to see what other hedge funds are holding ISRG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.